HDAC3 Regulates DNMT1 Expression in Multiple Myeloma: Therapeutic Implications

Leukemia - United Kingdom
doi 10.1038/leu.2017.144
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Evolving Therapeutic Role of Bisphosphonates in Multiple Myeloma

British Journal of Cancer
Cancer ResearchOncology
2005English

Clinical Implications of C-Maf Expression in Plasma Cells From Patients With Multiple Myeloma

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2017English

TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

The Therapeutic Potential of Cell Cycle Targeting in Multiple Myeloma

Oncotarget
Oncology
2017English

FOXM1 Is a Therapeutic Target in High-Risk Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Prognostic Value of CD56 Expression in Multiple Myeloma

Research in Oncology
2020English

Hdac3 Regulates Lymphovenous and Lymphatic Valve Formation

Journal of Clinical Investigation
Medicine
2017English

Determining Therapeutic Susceptibility in Multiple Myeloma by Single-Cell Mass Accumulation

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Bortezomib Induces Heme Oxygenase-1 Expression in Multiple Myeloma

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy